MX2020006459A - Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. - Google Patents

Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.

Info

Publication number
MX2020006459A
MX2020006459A MX2020006459A MX2020006459A MX2020006459A MX 2020006459 A MX2020006459 A MX 2020006459A MX 2020006459 A MX2020006459 A MX 2020006459A MX 2020006459 A MX2020006459 A MX 2020006459A MX 2020006459 A MX2020006459 A MX 2020006459A
Authority
MX
Mexico
Prior art keywords
fused ring
ring compounds
diaryl substituted
c5ar inhibitors
c5ar
Prior art date
Application number
MX2020006459A
Other languages
English (en)
Inventor
Christopher W Lange
Venkat Reddy Mali
Sreenivas Punna
Yibin Zeng
Pingchen Fan
Viengkham Malathong
Hiroko Tanaka
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2020006459A publication Critical patent/MX2020006459A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

La presente exposición proporciona, inter alia, los compuestos de la fórmula (I) Ver formula (I) o sales farmacéuticamente aceptables de los mismos que son moduladores del receptor de C5a. También se proporcionan composiciones farmacéuticas y métodos de uso que incluyen el tratamiento de enfermedades o trastornos que implican la activación patológica de C5a y aplicaciones no farmacéuticas.
MX2020006459A 2017-12-22 2018-12-20 Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. MX2020006459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609834P 2017-12-22 2017-12-22
PCT/US2018/066667 WO2019126424A1 (en) 2017-12-22 2018-12-20 DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS

Publications (1)

Publication Number Publication Date
MX2020006459A true MX2020006459A (es) 2020-11-06

Family

ID=66949183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006459A MX2020006459A (es) 2017-12-22 2018-12-20 Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.

Country Status (14)

Country Link
US (3) US10828285B2 (es)
EP (1) EP3728203B1 (es)
JP (1) JP7254082B2 (es)
KR (1) KR20200109316A (es)
CN (1) CN111788185A (es)
AU (1) AU2018388655C1 (es)
BR (1) BR112020012270A2 (es)
CA (1) CA3085946A1 (es)
IL (1) IL275500B2 (es)
MA (1) MA51331A (es)
MX (1) MX2020006459A (es)
SG (1) SG11202005791QA (es)
TW (1) TWI789470B (es)
WO (1) WO2019126424A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10683294B2 (en) 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
MA48803A (fr) 2017-05-31 2020-04-08 Chemocentryx Inc Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
AU2018326785B2 (en) 2017-09-03 2023-03-02 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
KR20200109316A (ko) 2017-12-22 2020-09-22 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
BR112020019822A2 (pt) * 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar
JP2023509336A (ja) 2019-12-19 2023-03-08 アクティブ バイオテック エービー 過剰血管新生に関連する眼疾患を治療する化合物
WO2021155841A1 (en) 2020-02-07 2021-08-12 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP3868368A1 (en) * 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
CA3192880A1 (en) 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
CN113143920B (zh) * 2021-05-25 2023-04-25 湖北工业大学 Ponesimod化合物在制备抗EV71病毒药物中的应用
CN116983264B (zh) * 2023-09-28 2023-12-22 中国农业科学院农产品加工研究所 一种二氢大麻二酚二苯甲酸酯的包埋体系及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DK27383A (da) * 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
ZA200301813B (en) * 2000-08-10 2004-06-22 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
CN1454086A (zh) 2000-09-29 2003-11-05 神经能质公司 高亲和性小分子C5a受体调节物
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
JP4196678B2 (ja) 2001-04-26 2008-12-17 味の素株式会社 複素環化合物
DE10293175D2 (de) 2001-07-19 2004-07-01 Luk Lamellen & Kupplungsbau System zum Ansteuern einer Komponente eines Getriebes eines Fahrzeuges unter Berücksichtigung eines Fluidverlustes
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
CA2479928A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
AU2003218374A1 (en) 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
CA2480082A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
WO2004016592A1 (en) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2005007087A2 (en) 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
UA95247C2 (ru) 2005-08-04 2011-07-25 Янссен Фармацевтика Н.В. Пиримидиновые соединения как модуляторы рецептора серотонина
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
WO2007051062A2 (en) 2005-10-28 2007-05-03 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
US20100035875A1 (en) 2008-06-20 2010-02-11 Bing-Yan Zhu Triazolopyridine jak inhibitor compounds and methods
SI2381778T1 (sl) 2008-12-22 2016-10-28 Chemocentryx, Inc. Antagonisti C5AR
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
ES2632975T3 (es) * 2010-06-24 2017-09-18 Chemocentryx, Inc. Antagonistas de C5aR
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
KR20150042271A (ko) 2012-08-16 2015-04-20 얀센 파마슈티카 엔.브이. N형 칼슘 채널 차단제로서의 치환된 피롤로피라졸
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN109310686B (zh) 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
MA48803A (fr) 2017-05-31 2020-04-08 Chemocentryx Inc Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
US10683294B2 (en) 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
US10589871B2 (en) 2017-09-25 2020-03-17 Hamilton Sundstrand Corporation Prognostic health monitoring and jam detection for use with an aircraft
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
KR20200109316A (ko) 2017-12-22 2020-09-22 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물
BR112020019822A2 (pt) * 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar

Also Published As

Publication number Publication date
US10828285B2 (en) 2020-11-10
JP7254082B2 (ja) 2023-04-07
IL275500A (en) 2020-08-31
TW201927782A (zh) 2019-07-16
EP3728203A4 (en) 2021-06-16
SG11202005791QA (en) 2020-07-29
CA3085946A1 (en) 2019-06-27
EP3728203A1 (en) 2020-10-28
US20190192491A1 (en) 2019-06-27
BR112020012270A2 (pt) 2020-11-24
WO2019126424A1 (en) 2019-06-27
IL275500B1 (en) 2023-01-01
AU2018388655B2 (en) 2022-11-24
TWI789470B (zh) 2023-01-11
AU2018388655C1 (en) 2023-03-23
IL275500B2 (en) 2023-05-01
CN111788185A (zh) 2020-10-16
JP2021506893A (ja) 2021-02-22
AU2018388655A1 (en) 2020-07-09
RU2020124093A (ru) 2022-01-25
MA51331A (fr) 2020-10-28
US11478460B2 (en) 2022-10-25
EP3728203B1 (en) 2024-03-13
US20210106568A1 (en) 2021-04-15
KR20200109316A (ko) 2020-09-22
US20230115912A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
MX2020010390A (es) Profarmacos de antagonistas de c5ar biciclicos fusionados.
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2018014185A (es) Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.
PH12017501668A1 (en) Bace1 inhibitors
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
PH12021550258A1 (en) Cdk8/19 inhibitors
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
CR20200183A (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.